Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGSWW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GeneDx Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GeneDx Holdings's regulatory disclosures and financial reporting.
GeneDx Holdings Corp. director Emily M. Leproust increased her equity stake through routine stock-based compensation. On June 18, 2026, she exercised 3,576 Restricted Stock Units (RSUs), receiving the same number of shares of Class A Common Stock for no cash consideration, bringing her direct holdings to 24,852 shares.
She also received a new grant of 4,248 RSUs, each representing a contingent right to one share of Class A Common Stock upon settlement. According to the award terms, this grant vests on the earlier of the 2027 annual stockholder meeting or the first anniversary of the grant date, subject to her continued service.
Fuchs Thomas reported acquisition or exercise transactions in this Form 4 filing.
GeneDx Holdings Corp. director Thomas Fuchs received an equity compensation award in the form of 4,248 restricted stock units on June 18, 2026. Each RSU represents a contingent right to receive one share of Class A common stock upon settlement for no cash payment.
The entire award will vest on the earlier of the company’s 2027 annual stockholder meeting or the first anniversary of the grant date, as long as Fuchs continues to serve the company through that date. If service ends before vesting, the units may be cancelled rather than vest. Following this grant, Fuchs is reported as holding 4,248 RSUs, and no open‑market purchases or sales are disclosed in this filing.
GeneDx Holdings Corp. director and 10% owner Eli Casdin reported equity compensation activity involving GeneDx Class A Common Stock and restricted stock units. He exercised 3,576 RSUs into 3,576 shares of Class A Common Stock at no cost, increasing his direct common share holdings to 24,093 shares.
Casdin also received a new grant of 4,248 RSUs, each representing one future share of Class A Common Stock, which will vest on the earlier of the 2027 annual stockholder meeting or the first anniversary of the grant date, subject to continued service. In addition, entities associated with Casdin hold substantial indirect positions, including 3,707,164 shares through Casdin Partners Master Fund, LP, 333,144 shares through CMLS Holdings LLC, and 19,247 shares through Casdin Partners GP, LLC.
GeneDx Holdings Corp. reported the results of its Annual Meeting of Stockholders held on June 18, 2026. Stockholders elected Class II director Katherine Stueland to a three-year term, with 18,325,894 votes for and 5,893,466 votes withheld, and 3,409,327 broker non-votes.
Stockholders ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 27,466,639 votes for, 158,884 against and 3,164 abstentions. They also approved, on an advisory basis, the compensation of named executive officers, with 22,705,946 votes for and 1,471,593 against.
In an advisory vote on how often to hold future say-on-pay votes, 23,816,121 votes favored an annual vote, 24,246 favored every two years, 358,017 favored every three years, and 20,976 abstained. There were 29,675,547 Class A shares outstanding on the April 20, 2026 record date.
GeneDx Holdings Corp. chief financial officer Kevin Feeley reported an RSU vesting and related share sales to cover taxes. On June 16, 2026, 7,197 restricted stock units converted into an equal number of Class A Common shares for no cash consideration.
To fund tax withholding on this vesting, he sold a total of 3,729 Class A Common shares in open-market transactions at weighted-average prices between about $59 and $62 per share. After these sales, he beneficially owned 39,954 shares, plus RSUs covering up to 82,043 shares and options for up to 25,906 shares, all vesting under their existing terms.
GeneDx Holdings Corp. CEO Katherine Stueland reported routine equity compensation activity and related tax sales. On June 16, 2026, she exercised restricted stock units, acquiring 18,750 shares of Class A Common Stock upon RSU vesting.
On the same date she sold a total of 10,501 shares of Class A Common Stock in open-market transactions at weighted average prices around $59.75–$61.50 per share to cover tax withholding obligations from the RSU vesting, described as a non-discretionary “sell to cover” transaction. After these transactions, she beneficially owned 104,372 shares of Class A Common Stock, plus RSUs for up to 305,525 shares and options for up to 107,610 shares that vest under their terms.
GeneDx Holdings Corp. filed an initial insider ownership report for President Mark A. Gardner on a Form 3. The filing identifies Gardner as an officer of the company but does not list any specific transactions or derivative positions in the data provided.
GeneDx Holdings Corp. appointed Mark Gardner as President, effective June 15, 2026. He will oversee the company’s lab and commercial operations, report to CEO Katherine Stueland, and join the executive leadership team, while Bryan Dechairo shifts to a role leading product, technology and innovation initiatives.
Gardner previously led molecular genomics and oncology at Quest Diagnostics and held senior roles at Corza Medical, OmniSeq and Thermo Fisher Scientific. His employment agreement includes a $530,000 annual base salary, a target annual bonus equal to 65% of base salary, and $2,000,000 in restricted stock units vesting over four years, along with severance and change‑in‑control protections.
GeneDx Holdings Corp. chief financial officer Kevin Feeley reported RSU vesting and a related tax sale of common stock. On June 9, 2026, restricted stock units converted into 2,462 shares of Class A Common Stock for no cash consideration. On the same date, he sold 1,266 shares of Class A Common Stock at $53.77 per share in an open-market transaction to cover tax withholding obligations, described as a non-discretionary “sell to cover” event. After these transactions, he beneficially owned 36,486 shares of Class A Common Stock, as well as RSUs representing up to 89,240 additional shares and options to purchase up to 25,906 shares, which vest according to their terms. The RSUs vest in 6.25% quarterly installments, contingent on continued service.
GeneDx Holdings CEO Katherine Stueland exercised restricted stock units that converted into 6,546 shares of Class A Common Stock and sold 3,639 shares at about $53.77 per share. The sale was a “sell to cover” transaction to satisfy tax withholding obligations and was not discretionary. After these transactions, she beneficially owned 96,123 shares of common stock, RSUs for up to 324,275 additional shares, and options to purchase up to 107,610 shares that vest over time.